Targeted Therapy in the Palliative Setting of Colorectal Cancer—Survival and Medical Costs
(1) Background: Targeted therapy is used alone or together with chemotherapy in metastatic colorectal cancer. The aim of this study was to assess overall survival and medical costs in a cohort of patients with metastatic colorectal cancer. (2) Methods: Demographic and clinical characteristics of 337...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-06-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/11/3022 |
| _version_ | 1797597825507262464 |
|---|---|
| author | Kamuran Inci Bengt Nilsson Lars Ny Ulf Strömberg Nils Wilking Stefan Lindskog Daniel Giglio |
| author_facet | Kamuran Inci Bengt Nilsson Lars Ny Ulf Strömberg Nils Wilking Stefan Lindskog Daniel Giglio |
| author_sort | Kamuran Inci |
| collection | DOAJ |
| description | (1) Background: Targeted therapy is used alone or together with chemotherapy in metastatic colorectal cancer. The aim of this study was to assess overall survival and medical costs in a cohort of patients with metastatic colorectal cancer. (2) Methods: Demographic and clinical characteristics of 337 patients and pathological data of colorectal tumors were retrospectively collected in this population-based study. The overall survival and medical costs for patients receiving chemotherapy plus targeted therapy were compared with those for patients receiving chemotherapy only. (3) Results: Patients administered chemotherapy plus targeted therapy were less frail and had more often RAS wild-type tumors but had higher CEA levels than patients receiving chemotherapy only. No prolonged overall survival could be observed in patients receiving palliative targeted therapy. The medical costs for patients undergoing treatment with targeted therapy were significantly higher than for patients treated only with chemotherapy; they were especially higher in the group receiving targeted therapy early than late in the palliative setting. (4) Conclusions: The use of targeted therapy in metastatic colorectal cancer leads to significantly higher medical costs when used early in the palliative setting. No positive effects of the use of targeted therapy could be observed in this study; therefore, we suggest that targeted therapy be used in later lines of palliative therapy in metastatic colorectal cancer. |
| first_indexed | 2024-03-11T03:10:56Z |
| format | Article |
| id | doaj.art-cc7efe4ff8824b8e9d2e4078c6a67357 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T03:10:56Z |
| publishDate | 2023-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-cc7efe4ff8824b8e9d2e4078c6a673572023-11-18T07:39:40ZengMDPI AGCancers2072-66942023-06-011511302210.3390/cancers15113022Targeted Therapy in the Palliative Setting of Colorectal Cancer—Survival and Medical CostsKamuran Inci0Bengt Nilsson1Lars Ny2Ulf Strömberg3Nils Wilking4Stefan Lindskog5Daniel Giglio6Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg, SwedenDepartment of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg, SwedenDepartment of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg, SwedenDepartment of Research and Development, University of Gothenburg, Region Halland, 40530 Gothenburg, SwedenDepartment of Oncology-Pathology, Karolinska Institute, 17176 Stockholm, SwedenDepartment of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg, SwedenDepartment of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg, Sweden(1) Background: Targeted therapy is used alone or together with chemotherapy in metastatic colorectal cancer. The aim of this study was to assess overall survival and medical costs in a cohort of patients with metastatic colorectal cancer. (2) Methods: Demographic and clinical characteristics of 337 patients and pathological data of colorectal tumors were retrospectively collected in this population-based study. The overall survival and medical costs for patients receiving chemotherapy plus targeted therapy were compared with those for patients receiving chemotherapy only. (3) Results: Patients administered chemotherapy plus targeted therapy were less frail and had more often RAS wild-type tumors but had higher CEA levels than patients receiving chemotherapy only. No prolonged overall survival could be observed in patients receiving palliative targeted therapy. The medical costs for patients undergoing treatment with targeted therapy were significantly higher than for patients treated only with chemotherapy; they were especially higher in the group receiving targeted therapy early than late in the palliative setting. (4) Conclusions: The use of targeted therapy in metastatic colorectal cancer leads to significantly higher medical costs when used early in the palliative setting. No positive effects of the use of targeted therapy could be observed in this study; therefore, we suggest that targeted therapy be used in later lines of palliative therapy in metastatic colorectal cancer.https://www.mdpi.com/2072-6694/15/11/3022colorectal cancerpalliativebevacizumabEGFrsurvival |
| spellingShingle | Kamuran Inci Bengt Nilsson Lars Ny Ulf Strömberg Nils Wilking Stefan Lindskog Daniel Giglio Targeted Therapy in the Palliative Setting of Colorectal Cancer—Survival and Medical Costs Cancers colorectal cancer palliative bevacizumab EGFr survival |
| title | Targeted Therapy in the Palliative Setting of Colorectal Cancer—Survival and Medical Costs |
| title_full | Targeted Therapy in the Palliative Setting of Colorectal Cancer—Survival and Medical Costs |
| title_fullStr | Targeted Therapy in the Palliative Setting of Colorectal Cancer—Survival and Medical Costs |
| title_full_unstemmed | Targeted Therapy in the Palliative Setting of Colorectal Cancer—Survival and Medical Costs |
| title_short | Targeted Therapy in the Palliative Setting of Colorectal Cancer—Survival and Medical Costs |
| title_sort | targeted therapy in the palliative setting of colorectal cancer survival and medical costs |
| topic | colorectal cancer palliative bevacizumab EGFr survival |
| url | https://www.mdpi.com/2072-6694/15/11/3022 |
| work_keys_str_mv | AT kamuraninci targetedtherapyinthepalliativesettingofcolorectalcancersurvivalandmedicalcosts AT bengtnilsson targetedtherapyinthepalliativesettingofcolorectalcancersurvivalandmedicalcosts AT larsny targetedtherapyinthepalliativesettingofcolorectalcancersurvivalandmedicalcosts AT ulfstromberg targetedtherapyinthepalliativesettingofcolorectalcancersurvivalandmedicalcosts AT nilswilking targetedtherapyinthepalliativesettingofcolorectalcancersurvivalandmedicalcosts AT stefanlindskog targetedtherapyinthepalliativesettingofcolorectalcancersurvivalandmedicalcosts AT danielgiglio targetedtherapyinthepalliativesettingofcolorectalcancersurvivalandmedicalcosts |